Review Article

Analysis of 1-year Vertebral Fracture Risk Reduction Data in Treatments for Osteoporosis

Authors: Paul Miller, MD

Abstract

One-year vertebral fracture risk reduction from clinical trials in adults with postmenopausal or glucocorticoid-induced osteoporosis is reviewed. Data were obtained by conducting a literature search of osteoporosis medications using the MEDLINE database, bibliographies of selected citations, and recent meeting abstracts. The methodologic quality of the trials was assessed using recently published criteria for ranking evidence. In prospective analyses, the 1-year risk of new morphometric vertebral fractures was reduced by risedronate 5 mg/d in two 3-year studies in postmenopausal women with prevalent vertebral fracture, and in two 1-year studies in patients with or at risk for glucocorticoid-induced osteoporosis. The 1-year risk of clinical vertebral fractures was reduced by alendronate and raloxifene in post hoc analyses. Reduction of morphometrically identified vertebral fracture risk is a more stringent therapeutic goal than clinical vertebral fracture risk. Therefore, more weight should be given to data from studies that use the morphometry to assess vertebral fracture incidence.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

References 1. Consensus Development Conference. Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993; 94: 646–650.Consensus Development Conference.Diagnosis, prophylaxis, and treatment of osteoporosisAm J Med199394646 2. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285: 785–795.NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy.Osteoporosis prevention, diagnosis, and therapyJAMA2001285785 3. Wasnich RD. Vertebral fracture epidemiology. Bone 1996; 18( 3 Suppl): 179S–183S.WasnichRDVertebral fracture epidemiologyBone199618179S 4. Hodgson SF, Watts NB, Bilezikian JP, Clarke BL, Gray TK, Harris DW, et al. American Association of Clinical Endocrinologists 2001 medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis. Endocr Pract 2001; 7: 293–312.HodgsonSF]]WattsNB]]BilezikianJP]]ClarkeBL]]GrayTK]]HarrisDWAmerican Association of Clinical Endocrinologists 2001 medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosisEndocr Pract20017293 5. American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 1996; 39: 1791–1801.American College of Rheumatology Task Force on Osteoporosis Guidelines.Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosisArthritis Rheum1996391791 6. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 2001; 44: 1496–1503.American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 updateArthritis Rheum2001441496 7. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: Pathogenesis and management. Ann Intern Med 1990; 112: 352–364.LukertBP]]RaiszLGGlucocorticoid-induced osteoporosis: Pathogenesis and managementAnn Intern Med1990112352 8. Ross PD. Clinical consequences of vertebral fractures. Am J Med 1997; 103: 30S–43S.RossPDClinical consequences of vertebral fracturesAm J Med199710330S 9. Vogt TM, Ross PD, Palermo L, Musliner T, Genant HK, Black D, et al. Vertebral fracture prevalence among women screened for the Fracture Intervention Trial and a simple clinical tool to screen for undiagnosed vertebral fractures: Fracture Intervention Trial Research Group. Mayo Clin Proc 2000; 75: 888–896.VogtTM]]RossPD]]PalermoL]]MuslinerT]]GenantHK]]BlackDVertebral fracture prevalence among women screened for the Fracture Intervention Trial and a simple clinical tool to screen for undiagnosed vertebral fractures: Fracture Intervention Trial Research GroupMayo Clin Proc200075888 10. O'Neill TW, Silman AJ. Definition and diagnosis of vertebral fracture. J Rheumatol 1997; 24: 1208–1211.O'NeillTW]]SilmanAJDefinition and diagnosis of vertebral fractureJ Rheumatol1997241208 11. Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999; 42: 2309–2318.CohenS]]LevyRM]]KellerM]]BolingE]]EmkeyRD]]GreenwaldMRisedronate therapy prevents corticosteroid-induced bone loss: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group studyArthritis Rheum1999422309 12. Gold DT. The nonskeletal consequences of osteoporotic fractures: Psychologic and social outcomes. Rheum Dis Clin North Am 2001; 27: 255–262.GoldDTThe nonskeletal consequences of osteoporotic fractures: Psychologic and social outcomesRheum Dis Clin North Am200127255 13. Nevitt MC, Ettinger B, Black DM, Stone K, Jamal SA, Ensrud K, et al. The association of radiographically detected vertebral fractures with back pain and function: A prospective study. Ann Intern Med 1998; 128: 793–800.NevittMC]]EttingerB]]BlackDM]]StoneK]]JamalSA]]EnsrudKThe association of radiographically detected vertebral fractures with back pain and function: A prospective studyAnn Intern Med1998128793 14. Nevitt MC, Thompson DE, Black DM, Rubin SR, Ensrud K, Yates AJ, et al. Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures: Fracture Intervention Trial Research Group. Arch Intern Med 2000; 160: 77–85.NevittMC]]ThompsonDE]]BlackDM]]RubinSR]]EnsrudK]]YatesAJEffect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures: Fracture Intervention Trial Research GroupArch Intern Med200016077 15. Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001; 285: 320–323.LindsayR]]SilvermanSL]]CooperC]]HanleyDA]]BartonI]]BroySBRisk of new vertebral fracture in the year following a fractureJAMA2001285320 16. Genant HK, Li J, Wu CY, Shepherd JA. Vertebral fractures in osteoporosis: A new method for clinical assessment. J Clin Densitom 2000; 3: 281–290.GenantHK]]LiJ]]WuCY]]ShepherdJAVertebral fractures in osteoporosis: A new method for clinical assessmentJ Clin Densitom20003281 17. Greenspan SL, von Stetten E, Emond SK, Jones L, Parker RA. Instant vertebral assessment: A noninvasive dual X-ray absorptiometry technique to avoid misclassification and clinical mismanagement of osteoporosis. J Clin Densitom 2001; 4: 373–380.GreenspanSL]]von StettenE]]EmondSK]]JonesL]]ParkerRAInstant vertebral assessment: A noninvasive dual X-ray absorptiometry technique to avoid misclassification and clinical mismanagement of osteoporosisJ Clin Densitom20014373 18. Melton LJ III, Atkinson EJ, Cooper C, O'Fallon WM, Riggs BL. Vertebral fractures predict subsequent fractures. Osteoporos Int 1999; 10: 214–221.MeltonLJ]]AtkinsonEJ]]CooperC]]O'FallonWM]]RiggsBLVertebral fractures predict subsequent fracturesOsteoporos Int199910214 19. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA III, Berger M. Patients with prior fractures have an increased risk of future fractures: A summary of the literature and statistical synthesis. J Bone Miner Res 2000; 15: 721–739.KlotzbuecherCM]]RossPD]]LandsmanPB]]AbbottTA]]BergerMPatients with prior fractures have an increased risk of future fractures: A summary of the literature and statistical synthesisJ Bone Miner Res200015721 20. Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991; 114: 919–923.RossPD]]DavisJW]]EpsteinRS]]WasnichRDPre-existing fractures and bone mass predict vertebral fracture incidence in womenAnn Intern Med1991114919 21. Black DM, Arden NK, Palermo L, Pearson J, Cummings SR. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures: Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1999; 14: 821–828.BlackDM]]ArdenNK]]PalermoL]]PearsonJ]]CummingsSRPrevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures: Study of Osteoporotic Fractures Research GroupJ Bone Miner Res199914821 22. Kado DM, Browner WS, Palermo L, Nevitt MC, Genant HK, Cummings SR. Vertebral fractures and mortality in older women: A prospective study—Study of Osteoporotic Fractures Research Group. Arch Intern Med 1999; 159: 1215–1220.KadoDM]]BrownerWS]]PalermoL]]NevittMC]]GenantHK]]CummingsSRVertebral fractures a nd mortality in older women: A prospective study—Study of Osteoporotic Fractures Research GroupArch Intern Med19991591215 23. Walker-Bone K, Dennison E, Cooper C. Epidemiology of osteoporosis. Rheum Dis Clin North Am 2001; 27: 1–18.Walker-BoneK]]DennisonE]]CooperCEpidemiology of osteoporosisRheum Dis Clin North Am2001271 24. Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D. Risk of mortality following clinical fractures. Osteoporos Int 2000; 11: 556–561.CauleyJA]]ThompsonDE]]EnsrudKC]]ScottJC]]BlackDRisk of mortality following clinical fracturesOsteoporos Int200011556 25. McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med 1997; 126: 712–720.McQuayHJ]]MooreRAUsing numerical results from systematic reviews in clinical practiceAnn Intern Med1997126712 26. Siwek J, Gourlay ML, Slawson DC, Shaughnessy AF. How to write an evidence-based clinical review article. Am Fam Physician 2002; 65: 251–258.SiwekJ]]GourlayML]]SlawsonDC]]ShaughnessyAFHow to write an evidence-based clinical review articleAm Fam Physician200265251 27. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis: Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11: 83–91.ReginsterJ]]MinneHW]]SorensenOH]]HooperM]]RouxC]]BrandiMLRandomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis: Vertebral Efficacy with Risedronate Therapy (VERT) Study GroupOsteoporos Int20001183 28. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial—Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999; 282: 1344–1352.HarrisST]]WattsNB]]GenantHK]]McKeeverCD]]HangartnerT]]KellerMEffects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial—Vertebral Efficacy with Risedronate Therapy (VERT) Study GroupJAMA19992821344 29. Ismail AA, Cooper C, Felsenberg D, Varlow J, Kanis JA, Silman AJ, et al. Number and type of vertebral deformities: Epidemiological characteristics and relation to back pain and height loss—European Vertebral Osteoporosis Study Group. Osteoporos Int 1999; 9: 206–213.IsmailAA]]CooperC]]FelsenbergD]]VarlowJ]]KanisJA]]SilmanAJNumber and type of vertebral deformities: Epidemiological characteristics and relation to back pain and height loss—European Vertebral Osteoporosis Study GroupOsteoporos Int19999206 30. Genant HK. Assessment of vertebral fractures in osteoporosis research. J Rheumatol 1997; 24: 1212–1214.GenantHKAssessment of vertebral fractures in osteoporosis researchJ Rheumatol1997241212 31. Genant HK, Engelke K, Fuerst T, Gluer CC, Grampp S, Harris ST, et al. Noninvasive assessment of bone mineral and structure: state of the art. J Bone Miner Res 1996; 11: 707–730.GenantHK]]EngelkeK]]FuerstT]]GluerCC]]GramppS]]HarrisSTNoninvasive assessment of bone mineral and structure: state of the artJ Bone Miner Res199611707 32. Kiel D. Assessing vertebral fractures: National Osteoporosis Foundation Working Group on Vertebral Fractures. J Bone Miner Res 1995; 10: 518–523.KielDAssessing vertebral fractures: National Osteoporosis Foundation Working Group on Vertebral FracturesJ Bone Miner Res199510518 33. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women: Study of Osteoporotic Fractures Research Group. Ann Intern Med 1995; 122: 9–16.CauleyJA]]SeeleyDG]]EnsrudK]]EttingerB]]BlackD]]CummingsSREstrogen replacement therapy and fractures in older women: Study of Osteoporotic Fractures Research GroupAnn Intern Med19951229 34. Lufkin EG, Wahner HW, O'Fallon WM, Hodgson SF, Kotowicz MA, Lane AW, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992; 117: 1–9.LufkinEG]]WahnerHW]]O'FallonWM]]HodgsonSF]]KotowiczMA]]LaneAWTreatment of postmenopausal osteoporosis with transdermal estrogenAnn Intern Med19921171 35. Cauley JA, Black DM, Barrett-Connor E, Harris F, Shields K, Applegate W, et al. Effects of hormone replacement therapy on clinical fractures and height loss: The Heart and Estrogen/Progestin Replacement Study (HERS). Am J Med 2001; 110: 442–450.CauleyJA]]BlackDM]]Barrett-ConnorE]]HarrisF]]ShieldsK]]ApplegateWEffects of hormone replacement therapy on clinical fractures and height loss: The Heart and Estrogen/Progestin Replacement Study (HERS)Am J Med2001110442 36. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: A meta-analysis of randomized trials. JAMA 2001; 285: 2891–2897.TorgersonDJ]]Bell-SyerSEHormone replacement therapy and prevention of nonvertebral fractures: A meta-analysis of randomized trialsJAMA20012852891 37. U.S. Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: Recommendations and rationale. Ann Intern Med 2002; 137: 526–528.U.S. Preventive Services Task Force.Screening for osteoporosis in postmenopausal women: Recommendations and rationaleAnn Intern Med2002137526 38. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535–1541.BlackDM]]CummingsSR]]KarpfDB]]CauleyJA]]ThompsonDE]]NevittMCRandomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research GroupLancet19963481535 39. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 1998; 280: 2077–2082.CummingsSR]]BlackDM]]ThompsonDE]]ApplegateWB]]Barrett-ConnorE]]MuslinerTAEffect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention TrialJAMA19982802077 40. Chesnut CH III, Silverman S, Andriano K, Genant H, Gimona A, Harris S, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures Study—PROOF Study Group. Am J Med 2000; 109: 267–276.ChesnutCH]]SilvermanS]]AndrianoK]]GenantH]]GimonaA]]HarrisSA randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures Study—PROOF Study GroupAm J Med2000109267 41. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial—Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282: 637–645.EttingerB]]BlackDM]]MitlakBH]]KnickerbockerRK]]NickelsenT]]GenantHKReduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial—Multiple Outcomes of Raloxifene Evaluation (MORE) InvestigatorsJAMA1999282637 42. Procter & Gamble Pharmaceuticals. Actonel full prescribing information. Cincinnati, OH, Procter & Gamble Pharmaceuticals, 2002. 43. Watts NB, Adami S, Chesnut C. Risedronate reduces the risk of clinical vertebral fractures in just 6 months. J Bone Miner Res 2001; 16( Suppl 1)& colon; S407(abstract).WattsNB]]AdamiS]]ChesnutCRisedronate reduces the risk of clinical vertebral fractures in just 6 monthsJ Bone Miner Res200116S407 44. Chesnut C, Li Z, Meredith M, et al. Vertebral fracture risk reduction with risedronate in osteoporotic women: A meta-analysis of individual patient data across 5 studies. Presented at the Endocrine Society 84th Annual Meeting, June 19–22, 2002, San Francisco, CA (abstract P3-359). 45. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women: Hip Intervention Program Study Group. N Engl J Med 2001; 344: 333–340.McClungMR]]GeusensP]]MillerPD]]ZippelH]]BensenWG]]RouxCEffect of risedronate on the risk of hip fracture in elderly women: Hip Intervention Program Study GroupN Engl J Med2001344333 46. Cohen S, Roux C, Eastell R, et al. Risedronate rapidly and consistently reduces risk of vertebral fracture in patients with varying degree of osteoporotic severity. Arthritis Rheum 2000; 43( Suppl): S197(abstract).CohenS]]RouxC]]EastellRRisedronate rapidly and consistently reduces risk of vertebral fracture in patients with varying degree of osteoporotic severityArthritis Rheum200043S197 47. Merck & Co., Inc. Fosamax full prescribing information. West Point, PA, Merck & Co., Inc., 2000. 48. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis: The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333: 1437–1443.LibermanUA]]WeissSR]]BrollJ]]MinneHW]]QuanH]]BellNHEffect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis: The Alendronate Phase III Osteoporosis Treatment Study GroupN Engl J Med19953331437 49. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, et al. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial—FIT Research Group. J Clin Endocrinol Metab 2000; 85: 4118–4124.BlackDM]]ThompsonDE]]BauerDC]]EnsrudK]]MuslinerT]]HochbergMCFracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial—FIT Research GroupJ Clin Endocrinol Metab2000854118 50. Levis S, Quandt SA, Thompson D, Scott J, Schneider DL, Ross PD, et al. Alendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention trial. J Am Geriatr Soc 2002; 50: 409–415.LevisS]]QuandtSA]]ThompsonD]]ScottJ]]SchneiderDL]]RossPDAlendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention trialJ Am Geriatr Soc200250409 51. Quandt SA. Alendronate reduces the risk of clinical vertebral fracture in osteopenic women: Data from FIT. J Bone Min Res 2000; 15( Suppl 1): S551(abstract M400).QuandtSAAlendronate reduces the risk of clinical vertebral fracture in osteopenic women: Data from FITJ Bone Min Res200015S551 52. Eli Lilly and Co. Evista full prescribing information. Indianapolis, IN, Eli Lilly and Co., 2001. 53. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 1641–1647.DelmasPD]]BjarnasonNH]]MitlakBH]]RavouxAC]]ShahAS]]HusterWJEffects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal womenN Engl J Med19973371641 54. Pols H, Eastell R, Delmas P, et al. Early onset and sustained efficacy of raloxifene on incident vertebral fractures in postmenopausal women with osteoporosis: 4-year results from the MORE trial. Bone 2001; 28( Suppl): S85(abstract OR64).PolsH]]EastellR]]DelmasPEarly onset and sustained efficacy of raloxifene on incident vertebral fractures in postmenopausal women with osteoporosis: 4-year results from the MORE trialBone200128S85 55. Hall GM, Daniels M, Doyle DV, Spector TD. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 1994; 37: 1499–1505.HallGM]]DanielsM]]DoyleDV]]SpectorTDEffect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroidsArthritis Rheum1994371499 56. Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial—European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 2000; 15: 1006–1013.ReidDM]]HughesRA]]LaanRF]]Sacco-GibsonNA]]WenderothDH]]AdamiSEfficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial—European Corticosteroid-Induced Osteoporosis Treatment StudyJ Bone Miner Res2000151006 57. Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000; 67: 277–285.WallachS]]CohenS]]ReidDM]]HughesRA]]HoskingDJ]]LaanRFEffects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapyCalcif Tissue Int200067277 58. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis: Glucocorticoid-induced Osteoporosis Intervention Study Group. N Engl J Med 1998; 339: 292–299.SaagKG]]EmkeyR]]SchnitzerTJ]]BrownJP]]HawkinsF]]GoemaereSAlendronate for the prevention and treatment of glucocorticoid-induced osteoporosis: Glucocorticoid-induced Osteoporosis Intervention Study GroupN Engl J Med1998339292 59. Guyatt GH. Evidence-based management of patients with osteoporosis. J Clin Densitom 1998; 1: 395–402.GuyattGHEvidence-based management of patients with osteoporosisJ Clin Densitom19981395 60. Ensrud KE, Thompson DE, Cauley JA, Nevitt MC, Kado DM, Hochberg MC, et al. Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass: Fracture Intervention Trial Research Group. J Am Geriatr Soc 2000; 48: 241–249.EnsrudKE]]ThompsonDE]]CauleyJA]]NevittMC]]KadoDM]]HochbergMCPrevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass: Fracture Intervention Trial Research GroupJ Am Geriatr Soc200048241 61. Felson DT. Bias in meta-analytic research. J Clin Epidemiol 1992; 45: 885–892.FelsonDTBias in meta-analytic researchJ Clin Epidemiol199245885 62. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000; 355: 1064–1069.AssmannSF]]PocockSJ]]EnosLE]]KastenLESubgroup analysis and other (mis)uses of baseline data in clinical trialsLancet20003551064 &NA; You're either part of the solution Or a part of the problem.—Eldridge Cleaver